{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:26:35Z","timestamp":1785327995949,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic lupus erythematosus (SLE)\u00a0is a devastating autoimmune disorder associated with severe organ damage. The abnormality of T cell apoptosis is considered as an important pathogenetic mechanism of SLE. Norcantharidin (NCTD), a derivative of Cantharidin, is an efficacious anti-cancer drug by inhibiting cell proliferation and inducing cell apoptosis. Besides, NCTD has also been proved to protect the function of kidneys, while damaged renal function is the most important predictor of morbidity and mortality in SLE. All these suggest the potential effects of NCTD in SLE treatment. In this study we investigated whether NCTD exerted therapeutic effects in a mouse SLE model. Lupus prone female MRL\/<jats:italic>lpr<\/jats:italic> mice were treated with NCTD (1, 2\u2009mg\u00b7kg<jats:sup>\u22121<\/jats:sup>\u00b7d<jats:sup>\u22121<\/jats:sup>, ip) for 8 weeks. We showed that NCTD administration significantly decreased mortality rate, diminished the expression of anti-dsDNA IgG antibody, a diagnostic marker for SLE, as well as restored renal structure and function in MRL\/<jats:italic>lpr<\/jats:italic> mice. Moreover, NCTD administration dose-dependently inhibited lymphoproliferation and T cell accumulation in the spleens of MRL\/<jats:italic>lpr<\/jats:italic> mice. We further revealed that NCTD specifically inhibited DN T cell proliferation and Th17 cell differentiation both via blocking activation of signal transducer and activator of transcription 3 (STAT3) signaling pathway. On the other hand, NCTD did not affect T cell apoptosis in MRL\/<jats:italic>lpr<\/jats:italic> mice. Taken together, our data suggest that NCTD may be as a promising therapeutic drug through targeting T cells for the treatment of SLE.<\/jats:p>","DOI":"10.1038\/s41401-021-00773-7","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T09:04:42Z","timestamp":1632301482000},"page":"1521-1533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Norcantharidin ameliorates the development of murine lupus via inhibiting the generation of IL-17 producing cells"],"prefix":"10.1038","volume":"43","author":[{"given":"Li-jun","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-xing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-ping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"773_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02672-0","volume":"9","author":"HD Brightbill","year":"2018","unstructured":"Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, et al. NF-\u03baB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat Commun. 2018;9:179.","journal-title":"Nat Commun"},{"key":"773_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.clim.2015.04.004","volume":"158","author":"LJ Edwards","year":"2015","unstructured":"Edwards LJ, Mizui M, Kyttaris V. Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL\/lpr mice. Clin Immunol. 2015;158:221\u201330.","journal-title":"Clin Immunol"},{"key":"773_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41591-018-0254-9","volume":"25","author":"S Caielli","year":"2019","unstructured":"Caielli S, Veiga DT, Balasubramanian P, Athale S, Domic B, Murat E, et al. A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. Nat Med. 2019;25:75\u201381.","journal-title":"Nat Med"},{"key":"773_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41584-019-0356-x","volume":"16","author":"A Sharabi","year":"2020","unstructured":"Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol. 2020;16:100\u201312.","journal-title":"Nat Rev Rheumatol"},{"key":"773_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00005-015-0344-z","volume":"63","author":"J Tabarkiewicz","year":"2015","unstructured":"Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp. 2015;63:435\u201349.","journal-title":"Arch Immunol Ther Exp"},{"key":"773_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clim.2016.04.010","volume":"185","author":"T Koga","year":"2017","unstructured":"Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis. Clin Immunol. 2017;185:95\u20139.","journal-title":"Clin Immunol"},{"key":"773_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.immuni.2008.03.004","volume":"28","author":"W Ouyang","year":"2008","unstructured":"Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28:454\u201367.","journal-title":"Immunity"},{"key":"773_CR8","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/ar4277","volume":"15","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther. 2013;15:R97.","journal-title":"Arthritis Res Ther"},{"key":"773_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-015-0070-7","volume":"16","author":"A Zickert","year":"2015","unstructured":"Zickert A, Amoudruz P, Sundstrom Y, Ronnelid J, Malmstrom V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol. 2015;16:7.","journal-title":"BMC Immunol"},{"key":"773_CR10","doi-asserted-by":"crossref","unstructured":"Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont M-C, Ranchin B, et al. Retraction: Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and thepathophysiology of systemic lupus erythematosus. Nat Immunol. 2014;15:894.","DOI":"10.1038\/ni0914-894a"},{"key":"773_CR11","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1172\/JCI78085","volume":"125","author":"PR Burkett","year":"2015","unstructured":"Burkett PR, Meyer zu Horste G, Kuchroo VK. Pouring fuel on the fire: Th17 cells, Environ, and autoimmunity. J Clin Invest. 2015;125:2211\u20139.","journal-title":"J Clin Invest"},{"key":"773_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/ni.1741","volume":"10","author":"A Doreau","year":"2009","unstructured":"Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 2009;10:778\u201385.","journal-title":"Nat Immunol"},{"key":"773_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ni1552","volume":"9","author":"HC Hsu","year":"2008","unstructured":"Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2008;9:166\u201375.","journal-title":"Nat Immunol"},{"key":"773_CR14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716\u201330.","journal-title":"Nat Rev Rheumatol"},{"key":"773_CR15","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.4049\/jimmunol.0901533","volume":"183","author":"JC Crispin","year":"2009","unstructured":"Crispin JC, Tsokos GC. Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J Immunol. 2009;183:4675\u201381.","journal-title":"J Immunol"},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.4049\/jimmunol.1301005","volume":"191","author":"ZW Lai","year":"2013","unstructured":"Lai ZW, Borsuk R, Shadakshari A, Yu J, Dawood M, Garcia R, et al. Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol (Baltim, Md: 1950) 2013;191:2236\u201346.","journal-title":"J Immunol (Baltim, Md: 1950)"},{"key":"773_CR17","doi-asserted-by":"publisher","first-page":"624971","DOI":"10.3389\/fimmu.2020.624971","volume":"11","author":"T Koga","year":"2020","unstructured":"Koga T, Ichinose K, Kawakami A, Tsokos GC. Current insights and future prospects for targeting IL-17 to treat patients with systemic lupus erythematosus. Front Immunol. 2020;11:624971.","journal-title":"Front Immunol"},{"key":"773_CR18","doi-asserted-by":"publisher","first-page":"e48647","DOI":"10.15252\/embr.201948647","volume":"20","author":"R Agerholm","year":"2019","unstructured":"Agerholm R, Rizk J, Vinals MT, Bekiaris V. STAT3 but not STAT4 is critical for gammadeltaT17 cell responses and skin inflammation. EMBO Rep. 2019;20:e48647.","journal-title":"EMBO Rep."},{"key":"773_CR19","doi-asserted-by":"publisher","first-page":"e20191761","DOI":"10.1084\/jem.20191761","volume":"217","author":"CH Poholek","year":"2020","unstructured":"Poholek CH, Raphael I, Wu D, Revu S, Rittenhouse N, Uche UU, et al. Noncanonical STAT3 activity sustains pathogenic Th17 proliferation and cytokine response to antigen. J Exp Med. 2020;217:e20191761.","journal-title":"J Exp Med"},{"key":"773_CR20","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.178.8.4901","volume":"178","author":"AN Mathur","year":"2007","unstructured":"Mathur AN, Chang HC, Zisoulis DG, Stritesky GL, Yu Q, O\u2019Malley JT, et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol. 2007;178:4901\u20137.","journal-title":"J Immunol"},{"key":"773_CR21","doi-asserted-by":"publisher","first-page":"16814","DOI":"10.1073\/pnas.1414189111","volume":"111","author":"A Zanin Zhorov","year":"2014","unstructured":"Zanin Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111:16814\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"773_CR22","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1177\/0961203319877242","volume":"28","author":"N Yoshida","year":"2019","unstructured":"Yoshida N, He F, Kyttaris VC. T cell-specific STAT3 deficiency abrogates lupus nephritis. Lupus. 2019;28:1468\u201372.","journal-title":"Lupus"},{"key":"773_CR23","doi-asserted-by":"publisher","first-page":"105677","DOI":"10.1016\/j.intimp.2019.105677","volume":"74","author":"Y Du","year":"2019","unstructured":"Du Y, Du L, He Z, Zhou J, Wen C, Zhang Y. Cryptotanshinone ameliorates the pathogenesis of systemic lupus erythematosus by blocking T cell proliferation. Int Immunopharmacol. 2019;74:105677.","journal-title":"Int Immunopharmacol"},{"key":"773_CR24","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.3390\/ijms20143487","volume":"20","author":"CH Ahn","year":"2019","unstructured":"Ahn CH, Hong KO, Jin B, Lee W, Jung YC, Lee H, et al. Contribution of p38 MAPK pathway to norcantharidin-induced programmed cell death in human oral squamous cell carcinoma. Int J Mol Sci. 2019;20:3487.","journal-title":"Int J Mol Sci"},{"key":"773_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s11655-017-2792-2","volume":"24","author":"HB Shen","year":"2018","unstructured":"Shen HB, Huo ZJ, Bai YJ, He XJ, Li CH, Zhao YK, et al. Protective effect of norcantharidin on collagen-induced arthritis rats. Chin J Integr Med. 2018;24:278\u201383.","journal-title":"Chin J Integr Med"},{"key":"773_CR26","doi-asserted-by":"publisher","first-page":"e66356","DOI":"10.1371\/journal.pone.0066356","volume":"8","author":"Y Li","year":"2013","unstructured":"Li Y, Sun Y, Liu F, Sun L, Li J, Duan S, et al. Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition. PLoS One. 2013;8:e66356.","journal-title":"PLoS One"},{"key":"773_CR27","doi-asserted-by":"publisher","first-page":"17354","DOI":"10.1002\/jcb.28999","volume":"120","author":"H Xiao","year":"2019","unstructured":"Xiao H, Liao Y, Tang C, Xiao Z, Luo H, Li J, et al. RNA-Seq analysis of potential lncRNAs and genes for the anti-renal fibrotic effect of norcantharidin. J Cell Biochem. 2019;120:17354\u201367.","journal-title":"J Cell Biochem"},{"key":"773_CR28","first-page":"2199","volume":"7","author":"T Hou","year":"2015","unstructured":"Hou T, Xiao Z, Li Y, You YH, Li H, Liu YP, et al. Norcantharidin inhibits renal interstitial fibrosis by downregulating PP2Ac expression. Am J Transl Res. 2015;7:2199\u2013211.","journal-title":"Am J Transl Res"},{"key":"773_CR29","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1002\/art.11231","volume":"48","author":"H Hasegawa","year":"2003","unstructured":"Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL\/lpr mice. Arthritis Rheum. 2003;48:2555\u201366.","journal-title":"Arthritis Rheum"},{"key":"773_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0304-3835(97)00206-1","volume":"117","author":"EB Yang","year":"1997","unstructured":"Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett. 1997;117:93\u20138.","journal-title":"Cancer Lett"},{"key":"773_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/00001813-200503000-00008","volume":"16","author":"YJ Chen","year":"2005","unstructured":"Chen YJ, Shieh CJ, Tsai TH, Kuo CD, Ho LT, Liu TY, et al. Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs. 2005;16:293\u20139.","journal-title":"Anticancer Drugs"},{"key":"773_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/10837450.2018.1550788","volume":"24","author":"MH Xie","year":"2019","unstructured":"Xie MH, Ge M, Peng JB, Jiang XR, Wang DS, Ji LQ, et al. In-vivo anti-tumor activity of a novel poloxamer-based thermosensitive in situ gel for sustained delivery of norcantharidin. Pharm Dev Technol. 2019;24:623\u20139.","journal-title":"Pharm Dev Technol"},{"key":"773_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.4049\/jimmunol.1600659","volume":"198","author":"A Lu","year":"2017","unstructured":"Lu A, Li H, Niu J, Wu S, Xue G, Yao X, et al. Hyperactivation of the NLRP3 inflammasome in myeloid cells leads to severe organ damage in experimental lupus. J Immunol. 2017;198:1119\u201329.","journal-title":"J Immunol"},{"key":"773_CR34","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/art.30183","volume":"63","author":"Y Tada","year":"2011","unstructured":"Tada Y, Kondo S, Aoki S, Koarada S, Inoue H, Suematsu R, et al. Interferon regulatory factor 5 is critical for the development of lupus in MRL\/lpr mice. Arthritis Rheum. 2011;63:738\u201348.","journal-title":"Arthritis Rheum"},{"key":"773_CR35","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/art.30392","volume":"63","author":"LF Hou","year":"2011","unstructured":"Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL\/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum. 2011;63:2445\u201355.","journal-title":"Arthritis Rheum"},{"key":"773_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cei.12296","volume":"179","author":"OP Rekvig","year":"2015","unstructured":"Rekvig OP. Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks. Clin Exp Immunol. 2015;179:5\u201310.","journal-title":"Clin Exp Immunol"},{"key":"773_CR37","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1172\/JCI87037","volume":"126","author":"J Wang","year":"2016","unstructured":"Wang J, Mizui M, Zeng LF, Bronson R, Finnell M, Terhorst C, et al. Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. J Clin Invest. 2016;126:2077\u201392.","journal-title":"J Clin Invest"},{"key":"773_CR38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/cas.13900","volume":"110","author":"L Mei","year":"2019","unstructured":"Mei L, Sang W, Cui K, Zhang Y, Chen F, Li X. Norcantharidin inhibits proliferation and promotes apoptosis via c-Met\/Akt\/mTOR pathway in human osteosarcoma cells. Cancer Sci. 2019;110:582\u201395.","journal-title":"Cancer Sci"},{"key":"773_CR39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/0886022X.2017.1308257","volume":"39","author":"K Ye","year":"2017","unstructured":"Ye K, Wei Q, Gong Z, Huang Y, Liu H, Li Y, et al. Effect of norcantharidin on the proliferation, apoptosis, and cell cycle of human mesangial cells. Ren Fail. 2017;39:458\u201364.","journal-title":"Ren Fail"},{"key":"773_CR40","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.biopha.2018.04.100","volume":"103","author":"F Chen","year":"2018","unstructured":"Chen F, Wang S, Wei Y, Wu J, Huang G, Chen J, et al. Norcantharidin modulates the miR-30a\/Metadherin\/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone. Biomed Pharmacother. 2018;103:1092\u2013100.","journal-title":"Biomed Pharmacother"},{"key":"773_CR41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.immuni.2010.05.003","volume":"32","author":"L Durant","year":"2010","unstructured":"Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32:605\u201315.","journal-title":"Immunity"},{"key":"773_CR42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.40931","volume":"71","author":"DM Rohraff","year":"2019","unstructured":"Rohraff DM, He Y, Farkash EA, Schonfeld M, Tsou PS, Sawalha AH. Inhibition of EZH2 ameliorates lupus-like disease in MRL\/lpr mice. Arthritis Rheumatol. 2019;71:1681\u201390.","journal-title":"Arthritis Rheumatol"},{"key":"773_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1535370218824547","volume":"244","author":"M Larosa","year":"2019","unstructured":"Larosa M, Zen M, Gatto M, Jesus D, Zanatta E, Iaccarino L, et al. IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus. Exp Biol Med. 2019;244:42\u201351.","journal-title":"Exp Biol Med"},{"key":"773_CR44","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585\u2013600.","journal-title":"Nat Rev Immunol"},{"key":"773_CR45","doi-asserted-by":"publisher","first-page":"968549","DOI":"10.1155\/2013\/968549","volume":"2013","author":"N Qu","year":"2013","unstructured":"Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL- 22, and IL-23, in inflammatory diseases. Clin Dev Immunol. 2013;2013:968549.","journal-title":"Clin Dev Immunol"},{"key":"773_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/cr.2017.156","volume":"28","author":"H Xu","year":"2018","unstructured":"Xu H, Littman DR. New traffic light on Th17 avenue. Cell Res. 2018;28:139\u201340.","journal-title":"Cell Res"},{"key":"773_CR47","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1073\/pnas.1807484116","volume":"116","author":"Q Xu","year":"2019","unstructured":"Xu Q, Jin X, Zheng M, Rohila D, Fu G, Wen Z, et al. Phosphatase PP2A is essential for TH17 differentiation. Proc Natl Acad Sci USA. 2019;116:982.","journal-title":"Proc Natl Acad Sci USA"},{"key":"773_CR48","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.immuni.2020.01.010","volume":"52","author":"SS Evans","year":"2020","unstructured":"Evans SS, Appenheimer MM. A fever-Th17 cell immune axis: some SMADs like it hot. Immunity. 2020;52:209\u201311.","journal-title":"Immunity"},{"key":"773_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00313-6","volume":"7","author":"QY Zhang","year":"2017","unstructured":"Zhang QY, Yue XQ, Jiang YP, Han T, Xin HL. FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells. Sci Rep. 2017;7:396.","journal-title":"Sci Rep."},{"key":"773_CR50","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.cellsig.2012.05.009","volume":"24","author":"S Zhang","year":"2012","unstructured":"Zhang S, Li G, Ma X, Wang Y, Liu G, Feng L, et al. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal. 2012;24:1803\u20139.","journal-title":"Cell Signal"},{"key":"773_CR51","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.lfs.2009.09.003","volume":"85","author":"YJ Chen","year":"2009","unstructured":"Chen YJ, Tsai YM, Kuo CD, Ku KL, Shie HS, Liao HF. Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect. Life Sci. 2009;85:642\u201351.","journal-title":"Life Sci"},{"key":"773_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000112850","volume":"28","author":"FY Liu","year":"2008","unstructured":"Liu FY, Li Y, Peng YM, Ye K, Li J, Liu YH, et al. Norcantharidin ameliorates proteinuria, associated tubulointerstitial inflammation and fibrosis in protein overload nephropathy. Am J Nephrol. 2008;28:465\u201377.","journal-title":"Am J Nephrol"},{"key":"773_CR53","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2249.2010.04194.x","volume":"161","author":"WU Kim","year":"2010","unstructured":"Kim WU, Min SY, Hwang SH, Yoo SA, Kim KJ, Cho CS. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin Exp Immunol. 2010;161:453\u20138.","journal-title":"Clin Exp Immunol"},{"key":"773_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1368-8375(01)00129-4","volume":"39","author":"SH Kok","year":"2003","unstructured":"Kok SH, Hong CY, Kuo MY, Lee CH, Lee JJ, Lou IU, et al. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol. 2003;39:19\u201326.","journal-title":"Oral Oncol"},{"key":"773_CR55","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50:892\u2013906.","journal-title":"Immunity"},{"key":"773_CR56","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/eji.201242653","volume":"42","author":"A Ambrosi","year":"2012","unstructured":"Ambrosi A, Espinosa A, Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol. 2012;42:2274\u201384.","journal-title":"Eur J Immunol"},{"key":"773_CR57","doi-asserted-by":"publisher","first-page":"540","DOI":"10.4049\/jimmunol.1400931","volume":"193","author":"G Amarilyo","year":"2014","unstructured":"Amarilyo G, Lourenco EV, Shi FD, La Cava A. IL-17 promotes murine lupus. J Immunol. 2014;193:540\u20133.","journal-title":"J Immunol"},{"key":"773_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41534-1","volume":"9","author":"SY Lee","year":"2019","unstructured":"Lee SY, Lee SH, Seo HB, Ryu JG, Jung K, Choi JW, et al. Inhibition of IL-17 ameliorates systemic lupus erythematosus in Roquin(san\/san) mice through regulating the balance of TFH cells, GC B cells, Treg and Breg. Sci Rep. 2019;9:5227.","journal-title":"Sci Rep."},{"key":"773_CR59","doi-asserted-by":"publisher","first-page":"e124575","DOI":"10.1172\/jci.insight.124575","volume":"4","author":"S Slight-Webb","year":"2019","unstructured":"Slight-Webb S, Guthridge JM, Chakravarty EF, Chen H, Lu R, Macwana S, et al. Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients. JCI Insight. 2019;4:e124575.","journal-title":"JCI Insight"},{"key":"773_CR60","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1172\/JCI89281","volume":"127","author":"EA Ansa-Addo","year":"2017","unstructured":"Ansa-Addo EA, Zhang Y, Yang Y, Hussey GS, Howley BV, Salem M, et al. Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-beta signaling. J Clin Invest. 2017;127:1321\u201337.","journal-title":"J Clin Invest"},{"key":"773_CR61","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.4049\/jimmunol.1502043","volume":"196","author":"CL Ding","year":"2016","unstructured":"Ding CL, Chen XG, Dascani P, Hu XL, Bolli R, Zhang HG, et al. STAT3 signaling in B cells is critical for germinal center maintenance and contributes to the pathogenesis of murine models of lupus. J Immunol. 2016;196:4477\u201386.","journal-title":"J Immunol"},{"key":"773_CR62","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","volume":"9","author":"K Hofmann","year":"2018","unstructured":"Hofmann K, Clauder AK, Manz RA, Targeting B Cells and plasma cells in autoimmune diseases. Front Immunol. 2018;9:835.","journal-title":"Front Immunol"},{"key":"773_CR63","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41423-020-00540-4","volume":"18","author":"K Ma","year":"2020","unstructured":"Ma K, Du W, Xiao F, Han M, Huang E, Peng N, et al. IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis. Cell Mol Immunol. 2020;18:1739\u201350.","journal-title":"Cell Mol Immunol"},{"key":"773_CR64","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.it.2021.02.002","volume":"42","author":"J Choi","year":"2021","unstructured":"Choi J, Crotty S. Bcl-6-mediated transcriptional regulation of follicular helper T cells (TFH). Trends Immunol. 2021;42:336\u201349.","journal-title":"Trends Immunol"},{"key":"773_CR65","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1172\/JCI129018","volume":"130","author":"ZJ Wang","year":"2020","unstructured":"Wang ZJ, Zhao M, Yin JH, Liu LM, Hu LY, Huang Y, et al. E4BP4-mediated inhibition of T follicular helper cell differentiation is compromised in autoimmune diseases. J Clin Invest. 2020;130:3717\u201333.","journal-title":"J Clin Invest"},{"key":"773_CR66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2014.02.005","volume":"40","author":"JP Ray","year":"2014","unstructured":"Ray JP, Marshall HD, Laidlaw BJ, Staron MM, Kaech SM, Craft J. Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity. 2014;40:367\u201377.","journal-title":"Immunity"},{"key":"773_CR67","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-018-1690-0","volume":"20","author":"Q Niu","year":"2018","unstructured":"Niu Q, Huang ZC, Wu XJ, Jin YX, An YF, Li YM, et al. Enhanced IL-6\/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper\/T follicular regulatory cells in patients with rheumatoid arthritis. Arthritis Res Ther. 2018;20:200.","journal-title":"Arthritis Res Ther"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00773-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T08:40:27Z","timestamp":1654072827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00773-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00773-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}